{"id":"lidocaine-patch-1-8","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or erythema at application site"},{"rate":null,"effect":"Contact dermatitis"},{"rate":null,"effect":"Mild burning or stinging at application site"}]},"_chembl":{"chemblId":"CHEMBL79","moleculeType":"Small molecule","molecularWeight":"234.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lidocaine is a local anesthetic that penetrates the skin and underlying tissues to reversibly inhibit sodium influx through voltage-gated sodium channels in nociceptive nerve fibers. This prevents depolarization and propagation of action potentials, thereby reducing pain sensation in the treated area. The patch formulation provides sustained local delivery to minimize systemic absorption.","oneSentence":"Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission at the site of application.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:12.693Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postherpetic neuralgia (PHN)"},{"name":"Localized neuropathic pain"}]},"trialDetails":[{"nctId":"NCT04150536","phase":"PHASE1","title":"Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and Exercise","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2016-01-08","conditions":"Healthy","enrollment":12},{"nctId":"NCT04144192","phase":"PHASE1","title":"Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2014-04-28","conditions":"Healthy","enrollment":58},{"nctId":"NCT04319926","phase":"PHASE1","title":"Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2018-09-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT06030297","phase":"NA","title":"Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.","status":"UNKNOWN","sponsor":"University of Utah","startDate":"2022-11-01","conditions":"Peripheral Neuropathy","enrollment":301},{"nctId":"NCT04245371","phase":"PHASE4","title":"Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome","status":"COMPLETED","sponsor":"John Papakonstantinou, MD","startDate":"2020-02-24","conditions":"Carpal Tunnel Syndrome","enrollment":45},{"nctId":"NCT05106400","phase":"PHASE1","title":"Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2021-07-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT04784728","phase":"PHASE1","title":"Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2019-08-21","conditions":"Healthy","enrollment":24},{"nctId":"NCT04320173","phase":"PHASE1","title":"Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2017-02-14","conditions":"Healthy","enrollment":47},{"nctId":"NCT04312750","phase":"PHASE1","title":"Adhesion of Lidocaine Topical System 1.8%","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2015-12","conditions":"Healthy","enrollment":54},{"nctId":"NCT04149938","phase":"PHASE1","title":"Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2016-09-28","conditions":"Healthy","enrollment":54},{"nctId":"NCT01661296","phase":"PHASE4","title":"Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India","status":"COMPLETED","sponsor":"Sarder Patel Medical College","startDate":"2009-08","conditions":"Cutaneous Leishmaniasis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lidocaine topical system 1.8%","ZTlido"],"phase":"marketed","status":"active","brandName":"Lidocaine patch 1.8%","genericName":"Lidocaine patch 1.8%","companyName":"Scilex Pharmaceuticals, Inc.","companyId":"scilex-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission at the site of application. Used for Postherpetic neuralgia (PHN), Localized neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}